Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders (2010 - 2026)

Neurocrine Biosciences has reported Net Income towards Common Stockholders for 17 years, with the latest figure at $197.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 2405.06% year-over-year to $197.9 million; the trailing twelve-month figure through Mar 2026 stood at $668.6 million (up 118.64% YoY), and the FY2025 full-year result was $478.6 million, up 40.23% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $197.9 million, up from $153.7 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $209.5 million in Q3 2025, with the low at -$76.6 million in Q1 2023.
• Historically, Net Income towards Common Stockholders has averaged $83.6 million across 5 years, with a median of $89.0 million in 2022.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders tumbled 651.08% — and 2026, when it soared 2405.06%.
• Neurocrine Biosciences' Net Income towards Common Stockholders stood at $89.0 million in 2022, then jumped by 65.96% to $147.7 million in 2023, then slumped by 30.2% to $103.1 million in 2024, then surged by 49.08% to $153.7 million in 2025, then rose by 28.76% to $197.9 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $197.9 million (Q1 2026), $153.7 million (Q4 2025), and $209.5 million (Q3 2025), per Business Quant data.